Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives $78.60 Consensus Price Target from Analysts

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) have received a consensus rating of “Moderate Buy” from the fifteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation, eleven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $77.93.

Several equities research analysts recently issued reports on APLS shares. Jefferies Financial Group upgraded shares of Apellis Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price objective for the stock from $68.00 to $80.00 in a research report on Monday, February 5th. Mizuho reaffirmed a “neutral” rating and issued a $60.00 price target on shares of Apellis Pharmaceuticals in a research note on Wednesday, March 27th. JPMorgan Chase & Co. raised their price objective on Apellis Pharmaceuticals from $78.00 to $79.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. The Goldman Sachs Group upped their target price on shares of Apellis Pharmaceuticals from $65.00 to $90.00 and gave the company a “buy” rating in a research report on Tuesday, January 9th. Finally, Oppenheimer increased their target price on shares of Apellis Pharmaceuticals from $75.00 to $79.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 30th.

Apellis Pharmaceuticals Trading Down 7.3 %

Shares of APLS opened at $48.03 on Monday. The firm’s fifty day moving average is $60.54 and its two-hundred day moving average is $57.04. The stock has a market cap of $5.79 billion, a PE ratio of -10.72 and a beta of 0.88. The company has a quick ratio of 2.50, a current ratio of 3.10 and a debt-to-equity ratio of 0.48. Apellis Pharmaceuticals has a 52-week low of $19.83 and a 52-week high of $94.75.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Tuesday, February 27th. The company reported ($0.73) earnings per share for the quarter, hitting the consensus estimate of ($0.73). The business had revenue of $146.38 million for the quarter, compared to analysts’ expectations of $143.34 million. Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The business’s revenue for the quarter was up 545.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.50) EPS. Research analysts forecast that Apellis Pharmaceuticals will post -1.33 earnings per share for the current fiscal year.

Insider Transactions at Apellis Pharmaceuticals

In related news, CFO Timothy Eugene Sullivan sold 3,551 shares of Apellis Pharmaceuticals stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $65.00, for a total value of $230,815.00. Following the transaction, the chief financial officer now directly owns 95,675 shares in the company, valued at approximately $6,218,875. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 4,184 shares of the business’s stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $65.00, for a total transaction of $271,960.00. Following the transaction, the general counsel now owns 105,077 shares in the company, valued at approximately $6,830,005. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Timothy Eugene Sullivan sold 3,551 shares of the stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $65.00, for a total value of $230,815.00. Following the transaction, the chief financial officer now directly owns 95,675 shares of the company’s stock, valued at $6,218,875. The disclosure for this sale can be found here. Insiders sold 406,651 shares of company stock worth $25,130,257 over the last 90 days. 7.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of APLS. Cim Investment Management Inc. boosted its position in shares of Apellis Pharmaceuticals by 3.6% during the 1st quarter. Cim Investment Management Inc. now owns 4,744 shares of the company’s stock worth $313,000 after purchasing an additional 163 shares in the last quarter. Sippican Capital Advisors boosted its holdings in Apellis Pharmaceuticals by 1.1% during the fourth quarter. Sippican Capital Advisors now owns 16,004 shares of the company’s stock worth $958,000 after buying an additional 170 shares in the last quarter. Advisor Group Holdings Inc. grew its position in Apellis Pharmaceuticals by 6.9% during the fourth quarter. Advisor Group Holdings Inc. now owns 3,249 shares of the company’s stock worth $167,000 after buying an additional 209 shares during the period. Treasurer of the State of North Carolina increased its holdings in Apellis Pharmaceuticals by 0.5% in the third quarter. Treasurer of the State of North Carolina now owns 43,800 shares of the company’s stock valued at $1,666,000 after buying an additional 230 shares in the last quarter. Finally, First Horizon Advisors Inc. boosted its stake in shares of Apellis Pharmaceuticals by 69.0% during the 3rd quarter. First Horizon Advisors Inc. now owns 649 shares of the company’s stock worth $25,000 after acquiring an additional 265 shares in the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).